Tocilizumab in severe COVID-19
Nicola Lucio LiberatoAndrea De MonteGiuseppe Caravella
Abstract
1. Liu B, Li M, Zhou Z, et al. (2020). Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 111: 102452. Google Scholar
Metrics
Citation History
Topics
Related Documents
Tocilizumab for severe COVID-19 pneumonia
Jean‐Jacques MouradPhilippe Azria
Tocilizumab for severe COVID-19 pneumonia
Salvatore PianoRoberto VettorPaolo AngeliGaetano Paride ArcidiaconoDevis BenfaremoSilvia BettiniBenedetta Maria BonoraGiovanni BuccaAnna Maria CattelanLorenzo CerrutiAndrea DalbeniV. FrambaAnna Maria Carvalhas GabrielliCarmine GambinoFrancesca GhirardiniUmberto GnudiMM LuchettiAlessandro MantovaniSara MaresoMaria Cristina MariniAndréa MartiniMassimo MattioliLuciano MucciGiampaolo PernaFabio PresottoCaterina SensiRoberto SerraF SolianiRoberta StupiaElia VettoreMirko Zoncapè
Tocilizumab for severe COVID-19 pneumonia
Brian J. LipworthRory ChanChris RuiWen Kuo
Tocilizumab for severe COVID-19 pneumonia – Authors' reply
Giovanni GuaraldiMarianna MeschiariJovana MilićAlessandro Cozzi‐LepriCristina Mussini